NRI.TO : Summary for NUVO PHARMACEUTICALS INC - Yahoo Finance

U.S. Markets close in 3 hrs 50 mins

Nuvo Pharmaceuticals Inc. (NRI.TO)


Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
5.550.00 (0.00%)
As of 11:26 AM EST. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close5.55
Open5.66
Bid5.55 x
Ask5.64 x
Day's Range5.55 - 5.66
52 Week Range3.77 - 8.35
Volume4,609
Avg. Volume19,926
Market Cap63.85M
Beta-0.39
PE Ratio (TTM)22.56
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Nuvo Pharmaceuticals, Inc. :NRI-CA: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
    Capital Cube7 days ago

    Nuvo Pharmaceuticals, Inc. :NRI-CA: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016

    Categories: Yahoo Finance Get free summary analysis Nuvo Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Nuvo Pharmaceuticals, Inc. – Valeant Pharmaceuticals International Inc, Theratechnologies Inc., Cipher Pharmaceuticals Inc. and BELLUS Health Inc. (VRX-CA, TH-CA, CPH-CA and BLU-CA) that have also reported for this ... Read more (Read more...)

  • CNW Group20 days ago

    Nuvo Pharmaceuticals™ Inc. Appoints Jesse Ledger as President

    Nuvo Pharmaceuticals™ Inc. Appoints Jesse Ledger as President

  • PR Newswire20 days ago

    Nuvo Pharmaceuticals™ Inc. Appoints Jesse Ledger as President

    MISSISSAUGA, ON, Nov. 16, 2016 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (NRI.TO), formerly Nuvo Research Inc., a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that its board of directors has appointed Jesse Ledger to the position of President effective immediately. Mr. Ledger was previously Nuvo's Vice-President of Business Development.  In his new role, Mr. Ledger will assume additional operational responsibilities and lead the Company's initiative to diversify its revenue streams by out-licensing global rights for its lead product, Pennsaid 2% and by acquiring complementary products or businesses.  John London, who was previously Nuvo's President and Chief Executive Officer will continue to lead the Company as its CEO.